BB BIOTECH AG 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 2:36 pm Unchanged | 2024-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 8,517,839 15.100% | 0 (Unchanged) | Filing |
| 2024-02-13 06:05 am Purchase | 2023-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 8,517,839 16.500% | 3,140,000 (+58.39%) | Filing |
| 2023-02-14 4:14 pm Purchase | 2022-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 5,377,839 14.800% | 1,389,437 (+34.84%) | Filing |
| 2022-04-14 12:01 pm Purchase | 2022-04-11 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 3,988,402 11.000% | 548,402 (+15.94%) | Filing |
| 2022-02-11 4:57 pm Purchase | 2021-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 3,440,000 9.500% | 1,540,000 (+81.05%) | Filing |
| 2021-02-11 4:58 pm Purchase | 2021-02-03 | 13G | Black Diamond Therapeutics, Inc. BDTX | BB BIOTECH AG | 1,900,000 5.300% | 1,900,000 (New Position) | Filing |